Dupilumab Effective Against Prurigo Nodularis Out to 6 Months
Dupilumab (Dupixent) improved itch and skin lesions compared with placebo in people with prurigo nodularis (PN), according to a study in . The data, from a pair of phase 3 trials known as LIBERTY-PN PRIME and PRIME 2, came from adults with PN who had ≥20 nodules and severe itch that had not been adequately controlled by topical therapies.